Latest & greatest articles for testosterone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on testosterone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on testosterone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for testosterone

41. Testosterone for low sexual desire in nonsurgically postmenopausal women

Testosterone for low sexual desire in nonsurgically postmenopausal women Testosterone for low sexual desire in nonsurgically postmenopausal women Testosterone for low sexual desire in nonsurgically postmenopausal women Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Testosterone for low sexual desire in nonsurgically postmenopausal women. Lansdale: HAYES, Inc (...) .. Directory Publication. 2013 Authors' conclusions Endogenous androgens such as testosterone are thought to play a role in the regulation of sexual desire, and the goal of testosterone therapy for nonsurgically postmenopausal women is to increase sexual desire. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Females; Libido; Postmenopause; Sexual Dysfunctions, Psychological; Testosterone Language Published English Country of organisation United

Health Technology Assessment (HTA) Database.2013

42. Effects of testosterone and exercise on muscle leanness in eugonadal men with AIDS wasting.

Effects of testosterone and exercise on muscle leanness in eugonadal men with AIDS wasting. Effects of testosterone and exerc... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2000 ) Volume: 133 , Issue: 6 , Pages: 2166-2171 PubMed: Available from or Find this paper at: Abstract Loss of lean body and muscle mass characterizes the acquired immunodeficiency syndrome (AIDS) wasting syndrome (...) (AWS). Testosterone and exercise increase muscle mass in men with AWS, with unclear effects on muscle composition. We examined muscle composition in 54 eugonadal men with AWS who were randomized to 1) testosterone (200 mg im weekly) or placebo and simultaneously to 2) resistance training or no training in a 2 x 2 factorial design. At baseline and after 12 wk, we performed assessments of whole body composition by dual-energy X-ray absorptiometry and single-slice computed tomography for midthigh

Annals of Internal Medicine2013

46. What Is Andropause? Is Testosterone Supplementation the Answer in Older Men?

What Is Andropause? Is Testosterone Supplementation the Answer in Older Men? What Is Andropause? Is Testosterone Supplementation the Answer in Older Men? | Clinical Correlations What Is Andropause? Is Testosterone Supplementation the Answer in Older Men? September 20, 2012 By Kylie Birnbaum Faculty Peer Reviewed Women have long bemoaned menopause and its physiological, psychological, and sexual effects. Fortunately, hormone replacement therapy has provided relief for symptomatic women. Less (...) attention is paid to men, who also experience declines in their sex hormones. Decreased testosterone may explain many symptoms experienced by elderly men, such as poor sexual function and libido, decreased bone mineral density, fatigue, and decreased muscle mass and strength. Should physicians treat elderly men with testosterone replacement therapy? Late-onset hypogonadism, or “andropause,” is the gradual decline in testosterone levels in aging men. It differs from menopause in that it is a gradual

Clinical Correlations2012

47. Triptorelin pamoate (Salvacyl) - reversible reduction of testosterone to castrate levels in order to decrease sexual drive in adult men with severe sexual deviations

Triptorelin pamoate (Salvacyl) - reversible reduction of testosterone to castrate levels in order to decrease sexual drive in adult men with severe sexual deviations Published 11 June 2012 Statement of Advice triptorelin pamoate (Salvacyl ® ) 11.25mg powder and solvent for suspension for injection (No: 796/12) Ipsen Ltd 04 May 2012 ADVICE: in the absence of a submission from the holder of the marketing authorisation triptorelin pamoate (Salvacyl ® ) is not recommended for use within NHS (...) Scotland. Indication under review: reversible reduction of testosterone to castrate levels in order to decrease sexual drive in adult men with severe sexual deviations. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish

Scottish Medicines Consortium2012

48. Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial.

Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. 22396515 2012 03 07 2012 03 12 2016 10 17 1538-3598 307 9 2012 Mar 07 JAMA JAMA Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. 931-9 10.1001/jama.2012.227 Steroid 5α-reductase (...) inhibitors are used to treat benign prostatic hyperplasia and androgenic alopecia, but the role of 5α-dihydrotestosterone (DHT) in mediating testosterone's effects on muscle, sexual function, erythropoiesis, and other androgen-dependent processes remains poorly understood. To determine whether testosterone's effects on muscle mass, strength, sexual function, hematocrit level, prostate volume, sebum production, and lipid levels are attenuated when its conversion to DHT is blocked by dutasteride

JAMA2012

49. Effect of 1 Week of Sleep Restriction on Testosterone Levels in Young Healthy MenFREE

Effect of 1 Week of Sleep Restriction on Testosterone Levels in Young Healthy MenFREE 21632481 2011 06 02 2011 06 03 2017 02 20 1538-3598 305 21 2011 Jun 01 JAMA JAMA Effect of 1 week of sleep restriction on testosterone levels in young healthy men. 2173-4 10.1001/jama.2011.710 Leproult Rachel R Department of Medicine, University of Chicago, Chicago, Illinois, USA. Van Cauter Eve E eng P60DK-020595 DK NIDDK NIH HHS United States 5R01HL72694-5 HL NHLBI NIH HHS United States M01 RR000055 RR NCRR (...) NIH HHS United States MO1-RR-00055 RR NCRR NIH HHS United States R01 HL072694 HL NHLBI NIH HHS United States P60 DK020595 DK NIDDK NIH HHS United States Journal Article Research Support, N.I.H., Extramural United States JAMA 7501160 0098-7484 3XMK78S47O Testosterone WI4X0X7BPJ Hydrocortisone AIM IM J Clin Endocrinol Metab. 2001 Feb;86(2):724-31 11158037 Sleep Med Rev. 2008 Oct;12(5):365-79 18519168 Psychiatry Res. 1989 Jan;27(1):89-99 2922449 J Clin Endocrinol Metab. 2005 Aug;90(8):4530-5 15914523

JAMA2011 Full Text: Link to full Text with Trip Pro

50. Reduction in 24-hour plasma testosterone levels in subjects who showered 15 or 30 minutes after application of testosterone gel.

Reduction in 24-hour plasma testosterone levels in subjects who showered 15 or 30 minutes after application of testosterone gel. 21361734 2011 03 02 2011 09 26 2013 11 21 1875-9114 31 3 2011 Mar Pharmacotherapy Pharmacotherapy Reduction in 24-hour plasma testosterone levels in subjects who showered 15 or 30 minutes after application of testosterone gel. 248-52 10.1592/phco.31.3.248 To investigate whether showering, to prevent the involuntary transfer of testosterone to others through skin (...) contact, either 15 or 30 minutes after application of testosterone gel would significantly affect plasma testosterone levels. Prospective 3-way crossover trial. University hospital in the Netherlands. Ten agonadal female-to-male transsexuals who had sex-reassignment surgery at least 3 months earlier. Subjects were randomized to one of three application regimens for testosterone gel 50 mg/day, each lasting 7 days: testosterone application after showering (standard regimen), shower was taken 30 minutes

EvidenceUpdates2011

52. Effects of Exogenous Testosterone Replacement Therapy on Time to ST Segment Depression and Myocardial Ischemia in Men With Chronic Stable Angina

Effects of Exogenous Testosterone Replacement Therapy on Time to ST Segment Depression and Myocardial Ischemia in Men With Chronic Stable Angina "Effects of Exogenous Testosterone Replacement Therapy on Time to ST Se" by Tanya N. Nestvogel < > > > > > Title Author Date of Award Spring 2-2011 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Torry Cobb, DHSc, MPH, PA-C Second Advisor Mary E. Von, DHEd, PA-C, DFAAPA Rights . Abstract (...) Background : Testosterone levels in men decline with age and low testosterone levels or hypogonadism can cause multiple negative effects and symptoms. Studies have shown that exogenous testosterone replacement therapy at physiological levels has a number of beneficial and protective effects on mood, libido, strength, lean body mass, bone health and cardiovascular health. One of the many cardiovascular benefits of testosterone therapy is its action as a vasodilator and effect on angina and exercise

Pacific University EBM Capstone Project2011

53. Incomplete testosterone suppression in prostate cancer.

Incomplete testosterone suppression in prostate cancer. Incomplete testosterone suppression in prostate cancer. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 21067409 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2010 Nov 11;363(20):1976. doi: 10.1056/NEJMc1010187. Incomplete testosterone suppression in prostate cancer. , . PMID: 21067409 DOI: [Indexed for MEDLINE] Free full text Publication type MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text

NEJM2010

54. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis

Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM CRD summary This review concluded that although haemoglobin (...) and haematocrit increased and high density lipoprotein cholesterol decreased in men who received testosterone therapy, the clinical significance of these findings was unclear and the evidence base was deficient. The review had some limitations, but the authors were appropriately cautious regarding the reliability of the results given the limitations of the original studies. Authors' objectives To determine the adverse events associated with testosterone therapy in adult men. Searching MEDLINE, EMBASE

DARE.2010

55. The Effect of Testosterone on Metabolic Syndrome and Type 2 Diabetes

The Effect of Testosterone on Metabolic Syndrome and Type 2 Diabetes "The Effect of Testosterone on Metabolic Syndrome and Type 2 Diabetes" by Alison Quammen < > > > > > Title Author Date of Award 8-14-2010 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mary Von PA-C Second Advisor Annjanette Sommers MS, PAC Third Advisor Rob Rosenow PharmD, OD Rights . Abstract Background: Metabolic syndrome (MetS) and diabetes type 2 (DM2 (...) a link between hypogonadism and metabolic syndrome and the next step is to evaluate if raising a man’s testosterone levels back to physiologic norms has any benefit in the treatment of metabolic syndrome or DM2. Methods: A comprehensive review of the literature was performed using the data bases: CINAHL, ovid - Medline, EBMR Multifile, Web of Science, PubMed and Google scholar. This produced a number of studies and the following exclusion criteria were applied to limit the search. Exclusion criteria

Pacific University EBM Capstone Project2010

56. Axiron (testosterone) topical solution

Axiron (testosterone) topical solution Drug Approval Package: Axiron (testosterone) NDA #022504 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Axiron (testosterone) topical solution Company: Acrux Pharma Pty Ltd. Application No.: 022504 Approval Date: 11/23/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2010

57. Fortesta (testosterone) Gel for topical use

Fortesta (testosterone) Gel for topical use Drug Approval Package: Fortesta (testosterone) NDA #021463 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Fortesta (testosterone) Gel for topical use, 10 mg of testosterone per pump actuation Company: Endo Pharmaceuticals, Inc. Application No.: 021463 Approval Date: 12/29/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF

FDA - Drug Approval Package2010

58. Adverse events associated with testosterone administration.

Adverse events associated with testosterone administration. 20592293 2010 07 21 2010 07 27 2016 12 07 1533-4406 363 2 2010 Jul 08 The New England journal of medicine N. Engl. J. Med. Adverse events associated with testosterone administration. 109-22 10.1056/NEJMoa1000485 Testosterone supplementation has been shown to increase muscle mass and strength in healthy older men. The safety and efficacy of testosterone treatment in older men who have limitations in mobility have not been studied (...) . Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less than 50 pg per milliliter (173 pmol per liter) were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months. Adverse events were categorized with the use of the Medical Dictionary for Regulatory Activities classification. The data and safety

NEJM2010 Full Text: Link to full Text with Trip Pro

59. Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial

Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial 19440073 2009 05 14 2009 08 03 2015 11 19 1533-712X 29 3 2009 Jun Journal of clinical psychopharmacology J Clin Psychopharmacol Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial. 216-21 10.1097/JCP.0b013e3181a39137 Mid-life onset male dysthymic disorder (DD) seems to be a distinct clinical condition (...) with limited therapeutic options. Testosterone replacement is mood-enhancing and has been proposed as an antidepressant therapy, though this strategy has received limited systematic study. We therefore conducted a six-week double-blind placebo-controlled clinical trial in 23 men with DD and with low or low-normal testosterone (T) level (i.e, screening total serum testosterone <350 ng/dL). Enrolled men were randomized to receive intramuscular injections of 200 mg of testosterone cypionate or placebo every

EvidenceUpdates2009

60. Testosterone undecanoate (Nebido) - Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests

Testosterone undecanoate (Nebido) - Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests

Scottish Medicines Consortium2009